SCHEMBL6034290

SCHEMBL6034290

CC(C)c1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1c(F)cccc1CC(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.35
TIPARP Q7Z3E1 1/20 0.34
PPARD Q03181 9/20 0.34
PPARA Q07869 5/20 0.34
GRIN2B Q13224 1/20 0.34
GCGR P47871 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
PPARG P37231 2/20 0.33
ROCK2 O75116 1/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR3C1 P04150 1/20 0.32
THRA P10827 1/20 0.32
THRB P10828 1/20 0.32
CYP2C9 P11712 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035590 0.93 GCGR (0.36) HDAC4TIPARPPPARDGCGRL3MBTL1
SCHEMBL6035873 0.92 GCGR (0.34) HDAC4TIPARPPPARDPPARAGCGR
SCHEMBL6034691 0.92 SMN1; SMN2 (0.36) HDAC4TIPARPPPARDPPARAGCGR
SCHEMBL6036239 0.92 HDAC4 (0.35) HDAC4TIPARPPPARDGCGRL3MBTL1
SCHEMBL6035321 0.91 PPARG (0.37) HDAC4TIPARPPPARDGCGRL3MBTL1
SCHEMBL6035182 0.91 HDAC4 (0.36) HDAC4TIPARPPPARDPPARAGCGR
SCHEMBL1633669 0.90 PPARG (0.43) HDAC4TIPARPPPARDPPARAPPARG
SCHEMBL6035119 0.90 SMN1; SMN2 (0.40) PPARDPPARAPPARGHPGDSMN1; SMN2
SCHEMBL6035459 0.89 PPARD (0.35) HDAC4TIPARPPPARDGCGRL3MBTL1
SCHEMBL6035784 0.88 PPARG (0.41) HDAC4TIPARPPPARDPPARAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 HDAC4 164/4885TIPARP 4833/4885PPARD 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.